{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T22:27:13Z","timestamp":1794263233428,"version":"4.9.0"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-94118-7","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T02:35:59Z","timestamp":1742351759000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Gout drives metabolic dysfunction-associated steatotic liver disease through gut microbiota and inflammatory mediators"],"prefix":"10.1038","volume":"15","author":[{"given":"Siyuan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunjia","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linan","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengsha","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijuan","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaokun","family":"Gang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guixia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,19]]},"reference":[{"key":"94118_CR1","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1016\/S0140-6736(21)00569-9","volume":"397","author":"N Dalbeth","year":"2021","unstructured":"Dalbeth, N., Gosling, A. L., Gaffo, A. & Abhishek, A. Gout. Lancet 397, 1843\u20131855. https:\/\/doi.org\/10.1016\/S0140-6736(21)00569-9 (2021).","journal-title":"Lancet"},{"key":"94118_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"Z Younossi","year":"2018","unstructured":"Younossi, Z. et al. Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention. Nat. Rev. Gastroenterol. Hepatol. 15, 11\u201320. https:\/\/doi.org\/10.1038\/nrgastro.2017.109 (2018).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"94118_CR3","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","volume":"62","author":"CD Byrne","year":"2015","unstructured":"Byrne, C. D. & Targher, G. NAFLD: A multisystem disease. J. Hepatol. 62, S47-64. https:\/\/doi.org\/10.1016\/j.jhep.2014.12.012 (2015).","journal-title":"J. Hepatol."},{"key":"94118_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejim.2020.07.006","volume":"80","author":"C Borghi","year":"2020","unstructured":"Borghi, C. et al. Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease. Eur. J. Intern. Med. 80, 1\u201311. https:\/\/doi.org\/10.1016\/j.ejim.2020.07.006 (2020).","journal-title":"Eur. J. Intern. Med."},{"key":"94118_CR5","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1136\/gutjnl-2023-330595","volume":"73","author":"G Targher","year":"2024","unstructured":"Targher, G., Byrne, C. D. & Tilg, H. MASLD: A systemic metabolic disorder with cardiovascular and malignant complications. Gut 73, 691\u2013702. https:\/\/doi.org\/10.1136\/gutjnl-2023-330595 (2024).","journal-title":"Gut"},{"key":"94118_CR6","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","volume":"79","author":"ME Rinella","year":"2023","unstructured":"Rinella, M. E. et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J. Hepatol. 79, 1542\u20131556. https:\/\/doi.org\/10.1016\/j.jhep.2023.06.003 (2023).","journal-title":"J. Hepatol."},{"key":"94118_CR7","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1053\/j.gastro.2019.05.064","volume":"157","author":"M Eslam","year":"2019","unstructured":"Eslam, M., Sanyal, A. J. & George, J. Toward more accurate nomenclature for fatty liver diseases. Gastroenterology 157, 590\u2013593. https:\/\/doi.org\/10.1053\/j.gastro.2019.05.064 (2019).","journal-title":"Gastroenterology"},{"key":"94118_CR8","doi-asserted-by":"publisher","first-page":"197","DOI":"10.7570\/jomes23052","volume":"32","author":"WK Chan","year":"2023","unstructured":"Chan, W. K. et al. Metabolic dysfunction-associated steatotic liver disease (MASLD): A state-of-the-art review. J. Obes. Metab. Syndr. 32, 197\u2013213. https:\/\/doi.org\/10.7570\/jomes23052 (2023).","journal-title":"J. Obes. Metab. Syndr."},{"key":"94118_CR9","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","volume":"397","author":"EE Powell","year":"2021","unstructured":"Powell, E. E., Wong, V. W. & Rinella, M. Non-alcoholic fatty liver disease. Lancet 397, 2212\u20132224. https:\/\/doi.org\/10.1016\/S0140-6736(20)32511-3 (2021).","journal-title":"Lancet"},{"key":"94118_CR10","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1038\/s42255-021-00501-9","volume":"3","author":"H Tilg","year":"2021","unstructured":"Tilg, H., Adolph, T. E., Dudek, M. & Knolle, P. Non-alcoholic fatty liver disease: The interplay between metabolism, microbes and immunity. Nat. Metab. 3, 1596\u20131607. https:\/\/doi.org\/10.1038\/s42255-021-00501-9 (2021).","journal-title":"Nat. Metab."},{"key":"94118_CR11","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1136\/annrheumdis-2013-204463","volume":"74","author":"CF Kuo","year":"2015","unstructured":"Kuo, C. F., Grainge, M. J., Mallen, C., Zhang, W. & Doherty, M. Rising burden of gout in the UK but continuing suboptimal management: A nationwide population study. Ann. Rheum. Dis. 74, 661\u2013667. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204463 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"94118_CR12","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1136\/ard.2007.081604","volume":"67","author":"JA Singh","year":"2008","unstructured":"Singh, J. A. & Strand, V. Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisation in US veterans. Ann. Rheum. Dis. 67, 1310\u20131316. https:\/\/doi.org\/10.1136\/ard.2007.081604 (2008).","journal-title":"Ann. Rheum. Dis."},{"key":"94118_CR13","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1161\/CIRCULATIONAHA.107.703389","volume":"116","author":"HK Choi","year":"2007","unstructured":"Choi, H. K. & Curhan, G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation 116, 894\u2013900. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.107.703389 (2007).","journal-title":"Circulation"},{"key":"94118_CR14","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/s41584-020-0441-1","volume":"16","author":"M Dehlin","year":"2020","unstructured":"Dehlin, M., Jacobsson, L. & Roddy, E. Global epidemiology of gout: Prevalence, incidence, treatment patterns and risk factors. Nat. Rev. Rheumatol. 16, 380\u2013390. https:\/\/doi.org\/10.1038\/s41584-020-0441-1 (2020).","journal-title":"Nat. Rev. Rheumatol."},{"key":"94118_CR15","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1111\/liv.13329","volume":"37","author":"K Wijarnpreecha","year":"2017","unstructured":"Wijarnpreecha, K. et al. Hyperuricaemia and risk of nonalcoholic fatty liver disease: A meta-analysis. Liver Int. 37, 906\u2013918. https:\/\/doi.org\/10.1111\/liv.13329 (2017).","journal-title":"Liver Int."},{"key":"94118_CR16","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.jare.2016.11.004","volume":"8","author":"UAAS El Din","year":"2017","unstructured":"El Din, U. A. A. S., Salem, M. M. & Abdulazim, D. O. Uric acid in the pathogenesis of metabolic, renal, and cardiovascular diseases: A review. J. Adv. Res. 8, 537\u2013548. https:\/\/doi.org\/10.1016\/j.jare.2016.11.004 (2017).","journal-title":"J. Adv. Res."},{"key":"94118_CR17","doi-asserted-by":"publisher","first-page":"683","DOI":"10.2147\/CLEP.S403314","volume":"15","author":"Q Sun","year":"2023","unstructured":"Sun, Q. et al. Association between serum uric acid and non-alcoholic fatty liver disease: An updated systematic review and meta-analysis. Clin. Epidemiol. 15, 683\u2013693. https:\/\/doi.org\/10.2147\/CLEP.S403314 (2023).","journal-title":"Clin. Epidemiol."},{"key":"94118_CR18","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41572-019-0115-y","volume":"5","author":"N Dalbeth","year":"2019","unstructured":"Dalbeth, N. et al. Gout. Nat. Rev. Dis. Primers 5, 69. https:\/\/doi.org\/10.1038\/s41572-019-0115-y (2019).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"94118_CR19","doi-asserted-by":"publisher","first-page":"1137822","DOI":"10.3389\/fimmu.2023.1137822","volume":"14","author":"YR Liu","year":"2023","unstructured":"Liu, Y. R., Wang, J. Q. & Li, J. Role of NLRP3 in the pathogenesis and treatment of gout arthritis. Front. Immunol. 14, 1137822. https:\/\/doi.org\/10.3389\/fimmu.2023.1137822 (2023).","journal-title":"Front. Immunol."},{"key":"94118_CR20","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nature04516","volume":"440","author":"F Martinon","year":"2006","unstructured":"Martinon, F., Petrilli, V., Mayor, A., Tardivel, A. & Tschopp, J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440, 237\u2013241. https:\/\/doi.org\/10.1038\/nature04516 (2006).","journal-title":"Nature"},{"key":"94118_CR21","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1038\/ajg.2013.104","volume":"108","author":"C Xu","year":"2013","unstructured":"Xu, C. et al. Prevalence and risk factors for the development of nonalcoholic fatty liver disease in a nonobese Chinese population: The Zhejiang Zhenhai Study. Am. J. Gastroenterol. 108, 1299\u20131304. https:\/\/doi.org\/10.1038\/ajg.2013.104 (2013).","journal-title":"Am. J. Gastroenterol."},{"key":"94118_CR22","doi-asserted-by":"publisher","first-page":"378","DOI":"10.5009\/gnl.2010.4.3.378","volume":"4","author":"JW Lee","year":"2010","unstructured":"Lee, J. W. et al. Serum uric acid as a predictor for the development of nonalcoholic Fatty liver disease in apparently healthy subjects: A 5-year retrospective cohort study. Gut Liver 4, 378\u2013383. https:\/\/doi.org\/10.5009\/gnl.2010.4.3.378 (2010).","journal-title":"Gut Liver"},{"key":"94118_CR23","doi-asserted-by":"publisher","first-page":"e11578","DOI":"10.1371\/journal.pone.0011578","volume":"5","author":"C Xu","year":"2010","unstructured":"Xu, C., Yu, C., Xu, L., Miao, M. & Li, Y. High serum uric acid increases the risk for nonalcoholic Fatty liver disease: A prospective observational study. PLoS One 5, e11578. https:\/\/doi.org\/10.1371\/journal.pone.0011578 (2010).","journal-title":"PLoS One"},{"key":"94118_CR24","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.diabet.2009.04.011","volume":"35","author":"K Lee","year":"2009","unstructured":"Lee, K. Relationship between uric acid and hepatic steatosis among Koreans. Diabetes Metab. 35, 447\u2013451. https:\/\/doi.org\/10.1016\/j.diabet.2009.04.011 (2009).","journal-title":"Diabetes Metab."},{"key":"94118_CR25","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1016\/j.jhep.2015.01.019","volume":"62","author":"C Xu","year":"2015","unstructured":"Xu, C. et al. Xanthine oxidase in non-alcoholic fatty liver disease and hyperuricemia: One stone hits two birds. J. Hepatol. 62, 1412\u20131419. https:\/\/doi.org\/10.1016\/j.jhep.2015.01.019 (2015).","journal-title":"J. Hepatol."},{"key":"94118_CR26","doi-asserted-by":"publisher","first-page":"466","DOI":"10.3109\/03009741003742797","volume":"39","author":"CF Kuo","year":"2010","unstructured":"Kuo, C. F. et al. Gout and risk of non-alcoholic fatty liver disease. Scand. J. Rheumatol. 39, 466\u2013471. https:\/\/doi.org\/10.3109\/03009741003742797 (2010).","journal-title":"Scand. J. Rheumatol."},{"key":"94118_CR27","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1007\/s10067-023-06510-1","volume":"42","author":"K Si","year":"2023","unstructured":"Si, K. et al. The risk of nonalcoholic fatty liver disease in gout patients with frequent flares: A retrospective cohort study. Clin. Rheumatol. 42, 1389\u20131395. https:\/\/doi.org\/10.1007\/s10067-023-06510-1 (2023).","journal-title":"Clin. Rheumatol."},{"key":"94118_CR28","doi-asserted-by":"publisher","first-page":"G42","DOI":"10.1152\/ajpgi.00443.2014","volume":"309","author":"Y Nakatsu","year":"2015","unstructured":"Nakatsu, Y. et al. The xanthine oxidase inhibitor febuxostat suppresses development of nonalcoholic steatohepatitis in a rodent model. Am. J. Physiol. Gastrointest. Liver Physiol. 309, G42-51. https:\/\/doi.org\/10.1152\/ajpgi.00443.2014 (2015).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"94118_CR29","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.semarthrit.2015.02.004","volume":"45","author":"SK Rai","year":"2015","unstructured":"Rai, S. K. et al. The economic burden of gout: A systematic review. Semin. Arthritis Rheum. 45, 75\u201380. https:\/\/doi.org\/10.1016\/j.semarthrit.2015.02.004 (2015).","journal-title":"Semin. Arthritis Rheum."},{"key":"94118_CR30","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ejim.2022.04.022","volume":"103","author":"S Copur","year":"2022","unstructured":"Copur, S., Demiray, A. & Kanbay, M. Uric acid in metabolic syndrome: Does uric acid have a definitive role?. Eur. J. Intern. Med. 103, 4\u201312. https:\/\/doi.org\/10.1016\/j.ejim.2022.04.022 (2022).","journal-title":"Eur. J. Intern. Med."},{"key":"94118_CR31","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jhep.2008.11.021","volume":"50","author":"Y Li","year":"2009","unstructured":"Li, Y., Xu, C., Yu, C., Xu, L. & Miao, M. Association of serum uric acid level with non-alcoholic fatty liver disease: A cross-sectional study. J. Hepatol. 50, 1029\u20131034. https:\/\/doi.org\/10.1016\/j.jhep.2008.11.021 (2009).","journal-title":"J. Hepatol."},{"key":"94118_CR32","doi-asserted-by":"publisher","first-page":"ITC65","DOI":"10.7326\/AITC201811060","volume":"169","author":"XJ Wang","year":"2018","unstructured":"Wang, X. J. & Malhi, H. Nonalcoholic Fatty Liver Disease. Ann Intern Med 169, ITC65\u2013ITC80. https:\/\/doi.org\/10.7326\/AITC201811060 (2018).","journal-title":"Ann Intern Med"},{"key":"94118_CR33","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1002\/hep.28356","volume":"63","author":"J Boursier","year":"2016","unstructured":"Boursier, J. et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology 63, 764\u2013775. https:\/\/doi.org\/10.1002\/hep.28356 (2016).","journal-title":"Hepatology"},{"key":"94118_CR34","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1002\/hep.26093","volume":"57","author":"L Zhu","year":"2013","unstructured":"Zhu, L. et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: A connection between endogenous alcohol and NASH. Hepatology 57, 601\u2013609. https:\/\/doi.org\/10.1002\/hep.26093 (2013).","journal-title":"Hepatology"},{"key":"94118_CR35","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s00394-017-1524-x","volume":"57","author":"F de Faria Ghetti","year":"2018","unstructured":"de Faria Ghetti, F. et al. Influence of gut microbiota on the development and progression of nonalcoholic steatohepatitis. Eur. J. Nutr. 57, 861\u2013876. https:\/\/doi.org\/10.1007\/s00394-017-1524-x (2018).","journal-title":"Eur. J. Nutr."},{"key":"94118_CR36","doi-asserted-by":"publisher","first-page":"e13646","DOI":"10.1111\/obr.13646","volume":"25","author":"X Su","year":"2024","unstructured":"Su, X. et al. Composition of gut microbiota and non-alcoholic fatty liver disease: A systematic review and meta-analysis. Obes. Rev. 25, e13646. https:\/\/doi.org\/10.1111\/obr.13646 (2024).","journal-title":"Obes. Rev."},{"key":"94118_CR37","doi-asserted-by":"publisher","first-page":"e13409","DOI":"10.1111\/obr.13409","volume":"23","author":"N Michels","year":"2022","unstructured":"Michels, N. et al. Human microbiome and metabolic health: An overview of systematic reviews. Obes. Rev. 23, e13409. https:\/\/doi.org\/10.1111\/obr.13409 (2022).","journal-title":"Obes. Rev."},{"key":"94118_CR38","doi-asserted-by":"publisher","first-page":"4982","DOI":"10.1038\/s41467-020-18754-5","volume":"11","author":"G Lee","year":"2020","unstructured":"Lee, G. et al. Distinct signatures of gut microbiome and metabolites associated with significant fibrosis in non-obese NAFLD. Nat. Commun. 11, 4982. https:\/\/doi.org\/10.1038\/s41467-020-18754-5 (2020).","journal-title":"Nat. Commun."},{"key":"94118_CR39","doi-asserted-by":"publisher","first-page":"e76341","DOI":"10.1371\/journal.pone.0076341","volume":"8","author":"EH Crost","year":"2013","unstructured":"Crost, E. H. et al. Utilisation of mucin glycans by the human gut symbiont Ruminococcus gnavus is strain-dependent. PLoS One 8, e76341. https:\/\/doi.org\/10.1371\/journal.pone.0076341 (2013).","journal-title":"PLoS One"},{"key":"94118_CR40","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/mi.2010.87","volume":"4","author":"RB Sartor","year":"2011","unstructured":"Sartor, R. B. Key questions to guide a better understanding of host-commensal microbiota interactions in intestinal inflammation. Mucosal Immunol. 4, 127\u2013132. https:\/\/doi.org\/10.1038\/mi.2010.87 (2011).","journal-title":"Mucosal Immunol."},{"key":"94118_CR41","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1002\/hep.28572","volume":"65","author":"F Del Chierico","year":"2017","unstructured":"Del Chierico, F. et al. Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach. Hepatology 65, 451\u2013464. https:\/\/doi.org\/10.1002\/hep.28572 (2017).","journal-title":"Hepatology"},{"key":"94118_CR42","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.3390\/foods11162534","volume":"11","author":"K Wang","year":"2022","unstructured":"Wang, K. et al. Sacha inchi oil press-cake protein hydrolysates exhibit anti-hyperuricemic activity via attenuating renal damage and regulating gut microbiota. Foods 11, 2534. https:\/\/doi.org\/10.3390\/foods11162534 (2022).","journal-title":"Foods"},{"key":"94118_CR43","doi-asserted-by":"publisher","first-page":"1287468","DOI":"10.3389\/fmicb.2023.1287468","volume":"14","author":"Q Lv","year":"2023","unstructured":"Lv, Q. et al. A dynamics association study of gut barrier and microbiota in hyperuricemia. Front. Microbiol. 14, 1287468. https:\/\/doi.org\/10.3389\/fmicb.2023.1287468 (2023).","journal-title":"Front. Microbiol."},{"key":"94118_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-021-02201-4","volume":"41","author":"Y Chen","year":"2022","unstructured":"Chen, Y. et al. Prevotellaceae produces butyrate to alleviate PD-1\/PD-L1 inhibitor-related cardiotoxicity via PPARalpha-CYP4X1 axis in colonic macrophages. J. Exp. Clin. Cancer Res. 41, 1. https:\/\/doi.org\/10.1186\/s13046-021-02201-4 (2022).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"94118_CR45","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1080\/17474124.2017.1343143","volume":"11","author":"M Vancamelbeke","year":"2017","unstructured":"Vancamelbeke, M. & Vermeire, S. The intestinal barrier: A fundamental role in health and disease. Expert Rev. Gastroenterol. Hepatol. 11, 821\u2013834. https:\/\/doi.org\/10.1080\/17474124.2017.1343143 (2017).","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"94118_CR46","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.jhep.2019.08.005","volume":"71","author":"J Mouries","year":"2019","unstructured":"Mouries, J. et al. Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development. J. Hepatol. 71, 1216\u20131228. https:\/\/doi.org\/10.1016\/j.jhep.2019.08.005 (2019).","journal-title":"J. Hepatol."},{"key":"94118_CR47","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1186\/1471-2164-15-1066","volume":"15","author":"MR Christopherson","year":"2014","unstructured":"Christopherson, M. R. et al. Unique aspects of fiber degradation by the ruminal ethanologen Ruminococcus albus 7 revealed by physiological and transcriptomic analysis. BMC Genomics 15, 1066. https:\/\/doi.org\/10.1186\/1471-2164-15-1066 (2014).","journal-title":"BMC Genomics"},{"key":"94118_CR48","first-page":"991","volume":"23","author":"CS Lieber","year":"1999","unstructured":"Lieber, C. S. Microsomal ethanol-oxidizing system (MEOS): The first 30 years (1968\u20131998)\u2014A review. Alcohol Clin. Exp. Res. 23, 991\u20131007 (1999).","journal-title":"Alcohol Clin. Exp. Res."},{"key":"94118_CR49","doi-asserted-by":"publisher","first-page":"102590","DOI":"10.1016\/j.ebiom.2019.11.051","volume":"51","author":"M Gurung","year":"2020","unstructured":"Gurung, M. et al. Role of gut microbiota in type 2 diabetes pathophysiology. EBioMedicine 51, 102590. https:\/\/doi.org\/10.1016\/j.ebiom.2019.11.051 (2020).","journal-title":"EBioMedicine"},{"key":"94118_CR50","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s10545-008-1015-6","volume":"31","author":"MM Wamelink","year":"2008","unstructured":"Wamelink, M. M., Struys, E. A. & Jakobs, C. The biochemistry, metabolism and inherited defects of the pentose phosphate pathway: A review. J. Inherit. Metab. Dis. 31, 703\u2013717. https:\/\/doi.org\/10.1007\/s10545-008-1015-6 (2008).","journal-title":"J. Inherit. Metab. Dis."},{"key":"94118_CR51","doi-asserted-by":"publisher","first-page":"eadi3332","DOI":"10.1126\/science.adi3332","volume":"383","author":"J Chen","year":"2024","unstructured":"Chen, J. et al. Hepatic glycogenesis antagonizes lipogenesis by blocking S1P via UDPG. Science 383, eadi3332. https:\/\/doi.org\/10.1126\/science.adi3332 (2024).","journal-title":"Science"},{"key":"94118_CR52","doi-asserted-by":"publisher","first-page":"100628","DOI":"10.1016\/j.jhepr.2022.100628","volume":"5","author":"J Jiao","year":"2023","unstructured":"Jiao, J. et al. Spatial molecular and cellular determinants of STAT3 activation in liver fibrosis progression in non-alcoholic fatty liver disease. JHEP Rep. 5, 100628. https:\/\/doi.org\/10.1016\/j.jhepr.2022.100628 (2023).","journal-title":"JHEP Rep."},{"key":"94118_CR53","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jhep.2022.08.022","volume":"78","author":"J Park","year":"2023","unstructured":"Park, J. et al. IL-6\/STAT3 axis dictates the PNPLA3-mediated susceptibility to non-alcoholic fatty liver disease. J. Hepatol. 78, 45\u201356. https:\/\/doi.org\/10.1016\/j.jhep.2022.08.022 (2023).","journal-title":"J. Hepatol."},{"key":"94118_CR54","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13000-018-0698-8","volume":"13","author":"E Choi","year":"2018","unstructured":"Choi, E. et al. Expression patterns of STAT3, ERK and estrogen-receptor alpha are associated with development and histologic severity of hepatic steatosis: A retrospective study. Diagn. Pathol. 13, 23. https:\/\/doi.org\/10.1186\/s13000-018-0698-8 (2018).","journal-title":"Diagn. Pathol."},{"key":"94118_CR55","doi-asserted-by":"publisher","first-page":"7243","DOI":"10.1073\/pnas.1507499112","volume":"112","author":"TH Su","year":"2015","unstructured":"Su, T. H. et al. Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition. Proc. Natl. Acad. Sci. U. S. A. 112, 7243\u20137248. https:\/\/doi.org\/10.1073\/pnas.1507499112 (2015).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"94118_CR56","doi-asserted-by":"publisher","first-page":"5537","DOI":"10.1158\/1078-0432.CCR-16-2253","volume":"23","author":"KH Jung","year":"2017","unstructured":"Jung, K. H. et al. Multifunctional effects of a small-molecule STAT3 inhibitor on NASH and hepatocellular carcinoma in mice. Clin. Cancer Res. 23, 5537\u20135546. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2253 (2017).","journal-title":"Clin. Cancer Res."},{"key":"94118_CR57","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","volume":"6","author":"X Hu","year":"2021","unstructured":"Hu, X., Li, J., Fu, M., Zhao, X. & Wang, W. The JAK\/STAT signaling pathway: from bench to clinic. Signal Transduct. Target. Ther. 6, 402. https:\/\/doi.org\/10.1038\/s41392-021-00791-1 (2021).","journal-title":"Signal Transduct. Target. Ther."},{"key":"94118_CR58","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/hep.28776","volume":"65","author":"V Ajmera","year":"2017","unstructured":"Ajmera, V. et al. Novel plasma biomarkers associated with liver disease severity in adults with nonalcoholic fatty liver disease. Hepatology 65, 65\u201377. https:\/\/doi.org\/10.1002\/hep.28776 (2017).","journal-title":"Hepatology"},{"key":"94118_CR59","doi-asserted-by":"publisher","first-page":"3000","DOI":"10.3390\/cells10113000","volume":"10","author":"M Iwaszko","year":"2021","unstructured":"Iwaszko, M., Bialy, S. & Bogunia-Kubik, K. Significance of interleukin (IL)-4 and IL-13 in inflammatory arthritis. Cells 10, 3000. https:\/\/doi.org\/10.3390\/cells10113000 (2021).","journal-title":"Cells"},{"key":"94118_CR60","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1111\/j.1365-2133.2009.09069.x","volume":"160","author":"T Morioka","year":"2009","unstructured":"Morioka, T. et al. IL-4\/IL-13 antagonist DNA vaccination successfully suppresses Th2 type chronic dermatitis. Br. J. Dermatol. 160, 1172\u20131179. https:\/\/doi.org\/10.1111\/j.1365-2133.2009.09069.x (2009).","journal-title":"Br. J. Dermatol."},{"key":"94118_CR61","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/s41574-022-00675-6","volume":"18","author":"E Barreby","year":"2022","unstructured":"Barreby, E., Chen, P. & Aouadi, M. Macrophage functional diversity in NAFLD\u2014More than inflammation. Nat. Rev. Endocrinol. 18, 461\u2013472. https:\/\/doi.org\/10.1038\/s41574-022-00675-6 (2022).","journal-title":"Nat. Rev. Endocrinol."},{"key":"94118_CR62","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/s1074-7613(02)00296-0","volume":"16","author":"TE North","year":"2002","unstructured":"North, T. E. et al. Runx1 expression marks long-term repopulating hematopoietic stem cells in the midgestation mouse embryo. Immunity 16, 661\u2013672. https:\/\/doi.org\/10.1016\/s1074-7613(02)00296-0 (2002).","journal-title":"Immunity"},{"key":"94118_CR63","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1182\/blood-2016-10-687830","volume":"129","author":"R Sood","year":"2017","unstructured":"Sood, R., Kamikubo, Y. & Liu, P. Role of RUNX1 in hematological malignancies. Blood 129, 2070\u20132082. https:\/\/doi.org\/10.1182\/blood-2016-10-687830 (2017).","journal-title":"Blood"},{"key":"94118_CR64","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/s13046-023-02814-x","volume":"42","author":"C She","year":"2023","unstructured":"She, C. et al. Combination of RUNX1 inhibitor and gemcitabine mitigates chemo-resistance in pancreatic ductal adenocarcinoma by modulating BiP\/PERK\/eIF2alpha-axis-mediated endoplasmic reticulum stress. J. Exp. Clin. Cancer Res. 42, 238. https:\/\/doi.org\/10.1186\/s13046-023-02814-x (2023).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"94118_CR65","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1097\/HEP.0000000000000041","volume":"77","author":"L Zhang","year":"2023","unstructured":"Zhang, L. et al. Runt-related transcription factor-1 ameliorates bile acid-induced hepatic inflammation in cholestasis through JAK\/STAT3 signaling. Hepatology 77, 1866\u20131881. https:\/\/doi.org\/10.1097\/HEP.0000000000000041 (2023).","journal-title":"Hepatology"},{"key":"94118_CR66","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.3390\/cells8101277","volume":"8","author":"S Kaur","year":"2019","unstructured":"Kaur, S. et al. Increased expression of RUNX1 in liver correlates with NASH activity score in patients with non-alcoholic steatohepatitis (NASH). Cells 8, 1277. https:\/\/doi.org\/10.3390\/cells8101277 (2019).","journal-title":"Cells"},{"key":"94118_CR67","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3389\/fnmol.2011.00051","volume":"4","author":"J Karar","year":"2011","unstructured":"Karar, J. & Maity, A. PI3K\/AKT\/mTOR pathway in angiogenesis. Front. Mol. Neurosci. 4, 51. https:\/\/doi.org\/10.3389\/fnmol.2011.00051 (2011).","journal-title":"Front. Mol. Neurosci."},{"key":"94118_CR68","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s13105-017-0589-6","volume":"73","author":"W Zhang","year":"2017","unstructured":"Zhang, W. et al. PI3K inhibition protects mice from NAFLD by down-regulating CMKLR1 and NLRP3 in Kupffer cells. J. Physiol. Biochem. 73, 583\u2013594. https:\/\/doi.org\/10.1007\/s13105-017-0589-6 (2017).","journal-title":"J. Physiol. Biochem."},{"key":"94118_CR69","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.cmet.2012.03.005","volume":"15","author":"FR Jornayvaz","year":"2012","unstructured":"Jornayvaz, F. R. & Shulman, G. I. Diacylglycerol activation of protein kinase Cepsilon and hepatic insulin resistance. Cell Metab. 15, 574\u2013584. https:\/\/doi.org\/10.1016\/j.cmet.2012.03.005 (2012).","journal-title":"Cell Metab."},{"key":"94118_CR70","doi-asserted-by":"publisher","first-page":"16381","DOI":"10.1073\/pnas.1113359108","volume":"108","author":"N Kumashiro","year":"2011","unstructured":"Kumashiro, N. et al. Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease. Proc. Natl. Acad. Sci. U. S. A. 108, 16381\u201316385. https:\/\/doi.org\/10.1073\/pnas.1113359108 (2011).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"94118_CR71","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1038\/s41598-020-57784-3","volume":"10","author":"T Nishikawa","year":"2020","unstructured":"Nishikawa, T. et al. Xanthine oxidase inhibition attenuates insulin resistance and diet-induced steatohepatitis in mice. Sci. Rep. 10, 815. https:\/\/doi.org\/10.1038\/s41598-020-57784-3 (2020).","journal-title":"Sci. Rep."},{"key":"94118_CR72","doi-asserted-by":"publisher","first-page":"e1001779","DOI":"10.1371\/journal.pmed.1001779","volume":"12","author":"C Sudlow","year":"2015","unstructured":"Sudlow, C. et al. UK biobank: An open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med 12, e1001779. https:\/\/doi.org\/10.1371\/journal.pmed.1001779 (2015).","journal-title":"PLoS Med"},{"key":"94118_CR73","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/s41586-022-05473-8","volume":"613","author":"MI Kurki","year":"2023","unstructured":"Kurki, M. I. et al. FinnGen provides genetic insights from a well-phenotyped isolated population. Nature 613, 508\u2013518. https:\/\/doi.org\/10.1038\/s41586-022-05473-8 (2023).","journal-title":"Nature"},{"key":"94118_CR74","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/ng.2500","volume":"45","author":"A Kottgen","year":"2013","unstructured":"Kottgen, A. et al. Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. Nat. Genet. 45, 145\u2013154. https:\/\/doi.org\/10.1038\/ng.2500 (2013).","journal-title":"Nat. Genet."},{"key":"94118_CR75","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41588-020-00763-1","volume":"53","author":"A Kurilshikov","year":"2021","unstructured":"Kurilshikov, A. et al. Large-scale association analyses identify host factors influencing human gut microbiome composition. Nat. Genet. 53, 156\u2013165. https:\/\/doi.org\/10.1038\/s41588-020-00763-1 (2021).","journal-title":"Nat. Genet."},{"key":"94118_CR76","doi-asserted-by":"publisher","first-page":"14357","DOI":"10.1038\/ncomms14357","volume":"8","author":"K Suhre","year":"2017","unstructured":"Suhre, K. et al. Connecting genetic risk to disease end points through the human blood plasma proteome. Nat. Commun. 8, 14357. https:\/\/doi.org\/10.1038\/ncomms14357 (2017).","journal-title":"Nat. Commun."},{"key":"94118_CR77","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1177\/0962280208092301","volume":"18","author":"L Meira-Machado","year":"2009","unstructured":"Meira-Machado, L., de Una-Alvarez, J., Cadarso-Suarez, C. & Andersen, P. K. Multi-state models for the analysis of time-to-event data. Stat. Methods Med. Res. 18, 195\u2013222. https:\/\/doi.org\/10.1177\/0962280208092301 (2009).","journal-title":"Stat. Methods Med. Res."},{"key":"94118_CR78","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1177\/0962280215597579","volume":"26","author":"S Burgess","year":"2017","unstructured":"Burgess, S., Small, D. S. & Thompson, S. G. A review of instrumental variable estimators for Mendelian randomization. Stat. Methods Med. Res. 26, 2333\u20132355. https:\/\/doi.org\/10.1177\/0962280215597579 (2017).","journal-title":"Stat. Methods Med. Res."},{"key":"94118_CR79","doi-asserted-by":"publisher","first-page":"949325","DOI":"10.3389\/fgene.2022.949325","volume":"13","author":"F Li","year":"2022","unstructured":"Li, F. et al. A mendelian randomization study with populations of European ancestry rules out a causal relationship between inflammatory bowel disease and colorectal cancer. Front. Genet. 13, 949325. https:\/\/doi.org\/10.3389\/fgene.2022.949325 (2022).","journal-title":"Front. Genet."},{"key":"94118_CR80","doi-asserted-by":"publisher","first-page":"186","DOI":"10.12688\/wellcomeopenres.15555.3","volume":"4","author":"S Burgess","year":"2019","unstructured":"Burgess, S. et al. Guidelines for performing Mendelian randomization investigations: update for summer 2023. Wellcome Open Res. 4, 186. https:\/\/doi.org\/10.12688\/wellcomeopenres.15555.3 (2019).","journal-title":"Wellcome Open Res."},{"key":"94118_CR81","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s10654-017-0255-x","volume":"32","author":"S Burgess","year":"2017","unstructured":"Burgess, S. & Thompson, S. G. Interpreting findings from Mendelian randomization using the MR-Egger method. Eur. J. Epidemiol. 32, 377\u2013389. https:\/\/doi.org\/10.1007\/s10654-017-0255-x (2017).","journal-title":"Eur. J. Epidemiol."},{"key":"94118_CR82","doi-asserted-by":"publisher","first-page":"e1007081","DOI":"10.1371\/journal.pgen.1007081","volume":"13","author":"G Hemani","year":"2017","unstructured":"Hemani, G., Tilling, K. & Davey Smith, G. Orienting the causal relationship between imprecisely measured traits using GWAS summary data. PLoS Genet 13, e1007081. https:\/\/doi.org\/10.1371\/journal.pgen.1007081 (2017).","journal-title":"PLoS Genet"},{"key":"94118_CR83","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1093\/ije\/dyw220","volume":"45","author":"J Bowden","year":"2016","unstructured":"Bowden, J. et al. Assessing the suitability of summary data for two-sample Mendelian randomization analyses using MR-Egger regression: the role of the I2 statistic. Int. J. Epidemiol. 45, 1961\u20131974. https:\/\/doi.org\/10.1093\/ije\/dyw220 (2016).","journal-title":"Int. J. Epidemiol."},{"key":"94118_CR84","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s10654-021-00757-1","volume":"36","author":"AR Carter","year":"2021","unstructured":"Carter, A. R. et al. Mendelian randomisation for mediation analysis: current methods and challenges for implementation. Eur. J. Epidemiol. 36, 465\u2013478. https:\/\/doi.org\/10.1007\/s10654-021-00757-1 (2021).","journal-title":"Eur. J. Epidemiol."},{"key":"94118_CR85","doi-asserted-by":"publisher","first-page":"681","DOI":"10.3238\/arztebl.m2023.0175","volume":"120","author":"T Tonnies","year":"2023","unstructured":"Tonnies, T., Schlesinger, S., Lang, A. & Kuss, O. Mediation analysis in medical research. Dtsch. Arztebl. Int. 120, 681\u2013687. https:\/\/doi.org\/10.3238\/arztebl.m2023.0175 (2023).","journal-title":"Dtsch. Arztebl. Int."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-94118-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-94118-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-94118-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T02:36:03Z","timestamp":1742351763000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-94118-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,19]]},"references-count":85,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["94118"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-94118-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,19]]},"assertion":[{"value":"25 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9395"}}